A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.

about

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis

P2860

Q58777537-487EF907-FFF2-4122-B1CD-BE77CDBF5281

P2860

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.

Item

http://www.wikidata.org/entity/Q39017592

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A cost-effectiveness analysis ...... eractivity disorder in the UK.

@en

A cost-effectiveness analysis ...... eractivity disorder in the UK.

@nl

type

Item

label

A cost-effectiveness analysis ...... eractivity disorder in the UK.

@en

A cost-effectiveness analysis ...... eractivity disorder in the UK.

@nl

prefLabel

A cost-effectiveness analysis ...... eractivity disorder in the UK.

@en

A cost-effectiveness analysis ...... eractivity disorder in the UK.

@nl

P1476

A cost-effectiveness analysis ...... eractivity disorder in the UK.

@en

P2093

Alain Joseph

http://www.w3.org/2001/XMLSchema#string

Evelina A Zimovetz

http://www.w3.org/2001/XMLSchema#string

Josephine A Mauskopf

http://www.w3.org/2001/XMLSchema#string

Rajeev Ayyagari

http://www.w3.org/2001/XMLSchema#string

P2860

European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

Childhood and persistent ADHD symptoms associated with educational failure and long-term occupational disability in adult ADHD.

A systematic review of the safety of lisdexamfetamine dimesylate.

Adult ADHD: evaluation and treatment in family medicine.

Health state utilities associated with adult attention-deficit/hyperactivity disorder.

Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.

The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder.

Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

P2888

s10198-016-0864-4

P304

21-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10198-016-0864-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28093662

http://www.w3.org/2001/XMLSchema#string

P921

attention

P932

5773633

http://www.w3.org/2001/XMLSchema#string

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.

about

P2860

P2860

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932